Microbix Biosystms (TSE:MBX) has released an update.
Microbix Biosystems Inc. has showcased a novel Hepatitis C Virus (HCV) Quality Assessment Product (QAP) at the American Diagnostic and Laboratory Medicine conference that offers room-temperature stability and ease of use in low-resource settings. This innovative QAP, designed for use with point-of-care tests and suitable for fingerstick blood samples, aims to enhance the accuracy of HCV diagnostics, particularly in regions where traditional lab facilities are scarce.
For further insights into TSE:MBX stock, check out TipRanks’ Stock Analysis page.
